Venture-Backed Resverlogix Spins Out Epigenetics Sub

The board of directors of Resverlogix Corp., a Calgary-based biopharmaceuticals company, has approved a proposal to spin out subsidiary RVX Therapeutics Inc. through an arrangement whereby investors receive one share in each of the two companies. The transaction is intended to give RVX Therapeutics the opportunity to fully leverage its epigenetics platform. Resverlogix has been backed by venture capital firms, including New York-based NGN Capital, since 2009.

CanadaNorth AmericaBriefs